|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:bioavailability
|
Not applicable (IV only)
|
|
gptkbp:brand
|
gptkb:Veklury
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:category
|
Antiviral agent
Nucleoside analog
Prodrug
|
|
gptkbp:contraindication
|
Hypersensitivity to remdesivir
|
|
gptkbp:developer
|
gptkb:Gilead_Sciences
|
|
gptkbp:eliminationHalfLife
|
1 hour (remdesivir), 27 hours (GS-441524)
|
|
gptkbp:hasAdministrationForm
|
solution for infusion
|
|
gptkbp:hasInChIKey
|
RWWYLEGWBNMMLJ-YSOARWBDSA-N
|
|
gptkbp:hasMolecularFormula
|
C27H35N6O8P
|
|
gptkbp:hasPharmacodynamics
|
Inhibits viral replication
|
|
gptkbp:hasPharmacokinetics
|
Rapidly distributed and metabolized
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](NC(=O)[C@@H](COP(=O)(OCCO)OCCO)N)C(=O)OCC1=CN(C2=NC=NC(=C21)N)C3CC3
|
|
gptkbp:hasUNII
|
53J0A3T2V9
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB15101
|
|
gptkbp:indication
|
gptkb:COVID-19
gptkb:Ebola_virus_infection_(investigational)
|
|
gptkbp:legalStatus
|
Prescription only
Patented
|
|
gptkbp:mechanismOfAction
|
RNA-dependent RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
Hepatic
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:name
|
gptkb:Remdesivir
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:proteinBinding
|
88-93%
|
|
gptkbp:PubChem_CID
|
gptkb:DB15101
121304016
CHEMBL2016761
D11973
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:Nausea
Hypersensitivity
Elevated liver enzymes
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:synonym
|
gptkb:GS-5734
|
|
gptkbp:target
|
SARS-CoV-2 RNA polymerase
|
|
gptkbp:bfsParent
|
gptkb:Cenobamate
|
|
gptkbp:bfsLayer
|
7
|